Government (of India) today said it will rollout a new pharma policy for bulk drugs in 10-15 days which will help the sector grow manifold over the next 5-7 years.
“The government is working on industry friendly bulk drug pharma policy. It is likely to be rolled out by the Prime Minister in next 10-15 days.” Pharmaceuticals Secretary V K Subburaj said at an event organised the PHD Chamber of Commerce and Industry.
Read more – The Economic Times
November 20, 2014 | Greg
The US Food & Drug Administration (FDA) is conducting an unannounced inspection of Dr Reddy’s Laboratories’ unit at Visakhapatnam since Tuesday evening, it is learnt. It could go on till the end of the week.
Read more – Business Standard News
November 19, 2014 | Greg
Patient advocates in India are protesting meetings being held this week between a trade group that advocates for intellectual property rights on behalf of global drug makers and Indian government officials, including leading judges, who decide patent policies and cases.
Read more – Pharmalot – WSJ
November 19, 2014 | Greg
The last five years have seen the highest volume growth in anti-diabetic medicines followed by those for treating semi-chronic ailments in urology urinary-related and dermatology skin care. According to data from industry body AIOCD, the Indian pharma market grew at a compound annual growth rate of 3.3 per cent in volume terms in the past five years. Against this, medicines for combating diabetes, urology and dermatological ailments have grown at more than double the industry growth rate.
Read more – The Economic Times
November 19, 2014 | Greg
A second experimental drug from Agios Pharmaceuticals (AGIO) designed to attack the “metabolism” of cancer cells has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.
Read more – TheStreet
November 19, 2014 | Greg
UBM India today announced the event highlights of CPhI India, which is co-located with P-MEC India, ICSE India and BioPh and slated for 2nd-4th December 2014 at the Bombay Exhibition Centre in Mumbai, India. The three-day industry event, wherein key players of the pharmaceutical sector worldwide will congregate to connect, share and ideate, will be preceded by the India Pharma Awards, scheduled for 1st December 2014 at the Westin Hotel, Mumbai.
Read more – PR Newswire India
November 18, 2014 | Greg
The probe initiated by the US legislature against Sun Pharma and Dr Reddy’s over the steep increase of their drug prices in the US market is set to intensify. A panel formed by the Congress will hold its first hearing on November 20.
Read more – Business Standard News
November 18, 2014 | Greg
Sun Pharmaceutical Industries and US-based Merck & Co have called off their more than three-year-old joint venture that aimed to bring innovative drugs to emerging markets, including India, sources with knowledge of the development said.
Read more – The Economic Times
November 18, 2014 | Greg
Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the Indian firm to launch copies of two drugs including AstraZeneca Plc’s heartburn pill Nexium, court documents showed.
Read more – The Economic Times
November 18, 2014 | Greg
The FDA said last week that it expects China, after almost 2 years of delays, to soon approve visas that will allow the agency to more than double its staff in China.
Read more – MassDevice
November 18, 2014 | Greg
The Tufts Center for the Study of Drug Development created the industry standard on R&D budgets when it pegged average R&D costs at close to $1 billion for each new drug. Today, Tufts researchers updated their figures and boosted the total to $2.9 billion.
Read more – FierceBiotech
November 18, 2014 | Greg
For years, there has been intense debate over what it costs to develop a new drug. And tomorrow, one think tank hopes to put the issue to rest. Of course, this remains to be seen.
Read more – Pharmalot – WSJ
November 17, 2014 | Greg
“With biologics declared as its main driver over the next few years, CDMO Wuxi is seeing rapid manufacturing growth and planning two new facilities in the next two years.”
Read more – Outsourcing-Pharma.com
November 17, 2014 | Greg
NEW DELHI: The government has launched a drive to promote the country’s ancient therapies as it seeks to cash in on the multi-billion dollar global market for holistic medicine.
India claims to have natural remedies for everything from cancer to the common cold, but ministers say it has failed to capitalise on its traditions as the world has woken up to alternative medicine.
Read more – Economic Times
November 17, 2014 | Greg
“Few industries have been shaped more by mergers and takeovers than pharmaceuticals. This is because developing drugs is such a high-risk business. Most potential medicines either fail to reach the market, or fail thereafter to recoup the cost of developing them. If a company does not have enough promising drugs in its research pipeline, its most obvious route to growth is to buy another firm. So, many of the world’s biggest drugmakers, such as Pfizer, Merck and GlaxoSmithKline (GSK), have been built through a succession of deals.”
Read more – The Economist
November 14, 2014 | Greg
